Oral treatment of nintedanib for interstitial lung diseases

April 4, 2020 0 By FM

Nintedanib oral capsules have been granted approval by the USFDA to treat patients with chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype.

The safety and effectiveness of nintedanib to treat chronic fibrosing ILD with a progressive phenotype in adults were evaluated in a randomized, double-blind, placebo-controlled study of 663 adults. The mean age of patients was 66 years and more patients were male (54%) than females. 

The primary test for effectiveness was the forced vital capacity, which is a measure of lung function. It is defined as the amount of air that can be forcibly exhaled from the lungs after taking the deepest breath possible. 

In the 52-week period, patients received either 150 milligrams of nintedanib twice a day or a placebo. After 52 weeks, people who received nintedanib had less lung function decline compared to those on the placebo.